Urban Data Lab

Urban Data Lab is a South Korean artificial intelligence company targeting the healthcare and life sciences sector with a focus on precision medicine. The company was established in November 2019 as a research-based spin-off, through a joint investment with ETRI Holdings, the technology commercialization arm of the Electronics and Telecommunications Research Institute (ETRI). The firm is led by CEO An Chi-seong.

The company's core business involves leveraging AI to analyze complex medical data, specifically in the field of digital pathology. Urban Data Lab has developed a cloud-based platform that manages and analyzes pathological images, assisting in cancer diagnosis and treatment. Its primary solution employs AI to analyze multi-omics and spatial information at a cellular level to discover novel biomarkers. These biomarkers are critical for developing personalized treatment plans, offering a more precise approach than traditional diagnostic methods. The technology aims to improve the accuracy and efficiency of pathologists, who are in short supply. The company has developed specific AI diagnostic assistance solutions for cancers such as 위암 (stomach cancer) and 유방암 (breast cancer) and is involved in a government-backed project to build a digital pathology AI platform for cancer treatment.

Urban Data Lab serves medical institutions, research centers, and pharmaceutical companies. Its business model appears to be centered on providing its AI-powered platform and solutions to these entities, likely through partnerships and service agreements. The company actively participates in major national R&D projects, collaborating with prominent institutions like the Catholic Medical Center, National Cancer Center, and Seoul National University Hospital. A significant milestone was the successful closing of a KRW 2.5 billion Series A funding round in July 2025, led by Naver Cloud, with participation from The Invention Lab and others. This capital is earmarked for enhancing its AI biomarker platform, hiring key R&D personnel, and expanding domestic and international partnerships. The firm also operates as a Premium Managed Service Provider for Naver Cloud, indicating a revenue stream from cloud infrastructure services and consulting.

Keywords: digital pathology, precision medicine, AI in healthcare, medical imaging analysis, cancer diagnosis, biomarker discovery, multi-omics data analysis, An Chi-seong, ETRI Holdings spin-off, clinical decision support, healthcare AI, Medipul랫폼, Naver Cloud partner, oncology AI, computational pathology, medical data platform, Korean biotech, life sciences AI, Series A funding, healthcare cloud services